Legend Biotech reports Q3 2026 results with revenue beat but GAAP loss
Legend Biotech announced its third‑quarter 2026 earnings on November 10. The company posted GAAP earnings of a $0.13 loss per share and revenue of $359.5 million, a 32% year‑over‑year increase. CEO Ingrid Zhang reiterated a goal of more than $5 billion in peak sales for CARVYKTI, while the firm also received FDA clearance for a new CAR‑T candidate, LB2501. The results were accompanied by a pre‑market share decline of about 13%.
Why it matters
The GAAP loss and modest earnings miss may pressure the stock in the short term, while the revenue beat and cash balance of $853 million provide a solid financial foundation for continued R&D and expansion. The company’s $5 billion peak‑sales outlook for CARVYKTI signals long‑term growth potential for investors.
Key facts
- 1GAAP earnings per share were a loss of $0.13, missing estimates by $0.13. seekingalpha.com
- 2Revenue was $359.5 million, a 32% year‑over‑year increase and a beat of $0.41 million versus estimates. seekingalpha.com
- 3Cash and cash equivalents totaled approximately $853 million as of September 30, 2026. seekingalpha.com
- 4Adjusted net income was $55.6 million, or $0.14 per diluted share, compared with an adjusted loss of $18.7 million a year earlier. finance.yahoo.com
- 5CEO Ingrid Zhang expects CARVYKTI to generate more than $5 billion in peak sales. finance.yahoo.com
- 6The company received FDA clearance to begin a clinical study of LB2501, an investigational CAR‑T therapy targeting CD19 and CD20. finance.yahoo.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.